Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis

Laukoetter, Mike G.; Mennigen, Rudolf; Hannig, CV; Osada, Nani; Rijcken, Emile; Vowinkel, Thorsten; Krieglstein, C. F.; Senninger, N.; Anthoni, Christoph; Bruewer, Matthias

doi:10.1007/s11605-010-1402-9

Cited by 171 publications

(111 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relative risk for colorectal cancer is increased in patients with CrD and UC compared to the non-IBD population and is associated with the anatomic expanse of inflammation, duration of disease, and presence of additional risk factors (e.g., primary sclerosing cholangitis) [8,9]. Patients with CrD have also an increased risk for small bowel cancer [10].…”

Section: Autoimmunity In Crohn's Diseasementioning

confidence: 99%

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Roggenbuck¹,

Reinhold

Schierack

et al. 2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Crohn's disease (CrD) and ulcerative colitis (UC) are the main inflammatory bowel diseases (IBD). IBDspecific humoral markers of autoimmunity in the form of autoantibodies have been reported first in the late 1950s by demonstrating the occurrence of autoimmunity in UC, while humoral autoimmunity in CrD can be traced back to the 1970s. Ever since, the pathophysiological role of autoimmune responses in IBDs has remained poorly understood. Notwithstanding, autoreactive responses play a major role in inflammation leading to overt IBD. In CrD, approximately 40% of patients and < 20% of patients with UC demonstrate loss of tolerance to antigens of the exocrine pancreas. Glycoprotein 2 (GP2) has been identified as a major autoantigenic target of the so-called pancreatic antibodies. The previously unsolved contradiction of pancreatic autoreactivity and intestinal inflammation in IBD was elucidated by demonstrating the expression of GP2 at the site thereof. Intriguingly, GP2 has been reported to be a receptor on microfold cells of intestinal Peyer's patches, which are believed to represent the origin of CrD inflammation. The development of immunoassays for the detection of antibodies to GP2 has paved the way to investigate the association of such antibodies with the clinical phenotype in CrD. Given the recently discovered immunomodulating role of GP2 in innate and adaptive intestinal immunity, this association can shed further light on the pathophysiology of IBD. In this context, the association of anti-GP2 autoantibodies as novel CrD-specific markers with the clinical phenotype in CrD will be discussed in this review.

show abstract

Section: Autoimmunity In Crohn's Diseasementioning

confidence: 99%

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Roggenbuck¹,

Reinhold

Schierack

et al. 2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Small bowel adenocarcinoma is not a common complication but carries poor prognosis in Crohn's disease. Its incidence ranges from (0.02-1.6 %) and increases with duration of Crohn's disease [2][3][4]. In this case, the progress of Crohn's disease is no longer than 1 year, and ileum cancer is proved by serendipitous biopsy.…”

Section: Discussionmentioning

confidence: 99%

Letter to the editor: one point cancer of ileal adenocarcinoma complicated from Crohn’s disease

Cai

2015

Int J Colorectal Dis

View full text Add to dashboard Cite

“…That is, in those CD subjects with extensive colitis, there appears to be somewhat of an increased risk, while those with disease limited to the small bowel appear to be at a baseline risk [19][20][21]. When all phenotypes of Crohn's disease are included, some studies place the relative risk of CRC between 2 and 3 [22][23][24], whereas others do not demonstrate any increased risk [17,25,26].…”

Section: Risk Factorsmentioning

confidence: 99%

Colorectal Adenocarcinoma and Inflammatory Bowel Disease: An Update and Review

Karmali¹

2015

Surgery Curr Res

View full text Add to dashboard Cite

Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis

Abstract: CD is a risk factor for colorectal cancer, small bowel cancer, and fistula cancer; however, compared to ulcerative colitis, cancer risk is moderate.

Cited by 171 publications

References 45 publications

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Letter to the editor: one point cancer of ileal adenocarcinoma complicated from Crohn’s disease

Colorectal Adenocarcinoma and Inflammatory Bowel Disease: An Update and Review

Contact Info

Product

Resources

About